Literature DB >> 12021335

Detection of CD4(+)- and CD8(+)-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release.

Jane C Steele1, Sally Roberts, Susan M Rookes, Phillip H Gallimore.   

Abstract

Human papillomavirus (HPV) antigens are expressed in epithelial cells at different stages of differentiation, and this may affect how they are handled by the immune system. We assessed the relative immunogenicities of four different HPV type 1 proteins: E6 and E7, which are made early in basal or parabasal cells; E4, which is made suprabasally in differentiating cells; and L1, a late protein which appears in the highly differentiated upper spinous layers. Pools of 15-mer peptides covering the primary sequences of all four proteins were used to screen 15 normal donors in enzyme-linked immunospot assays of gamma interferon release for both CD4(+)- and CD8(+)-T-cell reactivities. CD8(+)-T-cell responses were detected to the L1 protein in 7 of the 15 samples examined. No responses to E6, E7, or E4 were detected. CD4(+)-T-cell reactivities were again detected in 7 of the 15 donors. A broader spectrum of responses to E6 (three of seven), E4 (six of seven), and L1 (three of seven) was apparent, but there was no reactivity to E7. The predominant CD4(+) response was to E4. Reactivities were seen in some cases to corresponding regions on other common HPV types but were probably due to a multiple infection rather than to a cross-reaction. Antibodies to HPV1 virus-like particles were detected in 12 of the 15 (80%) donors, but antibody status did not correlate with T-cell reactivity. The differences in the relative immunogenicities of the four proteins revealed in this study are discussed in relation to how they may be processed and presented to the immune system by differentiating epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021335      PMCID: PMC136204          DOI: 10.1128/jvi.76.12.6027-6036.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity.

Authors:  S R Clarke
Journal:  J Leukoc Biol       Date:  2000-05       Impact factor: 4.962

3.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

Review 4.  Cross-presentation, dendritic cells, tolerance and immunity.

Authors:  W R Heath; F R Carbone
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

Authors:  J J Carter; L A Koutsky; J P Hughes; S K Lee; J Kuypers; N Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

6.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

7.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

8.  Abnormalities of cornified cell envelopes isolated from human papillomavirus type 11-infected genital epithelium.

Authors:  D R Brown; J T Bryan
Journal:  Virology       Date:  2000-05-25       Impact factor: 3.616

9.  Low level expression of human papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B- or T-helper immunological responses, or influence the outcome of immunisation with E6 protein.

Authors:  R Azoury-Ziadeh; K Herd; G J Fernando; P Lambert; I H Frazer; R W Tindle
Journal:  Virus Res       Date:  2001-03       Impact factor: 3.303

10.  Involuting common warts. Clinical and histopathologic findings.

Authors:  A Berman; R K Winkelmann
Journal:  J Am Acad Dermatol       Date:  1980-10       Impact factor: 11.527

View more
  8 in total

Review 1.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

2.  Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry.

Authors:  Mojca Bizjak; Or Bruck; Sonja Praprotnik; Shani Dahan; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.

Authors:  Belinda M Jackson-Thompson; Emilie Goguet; Eric D Laing; Cara H Olsen; Simon Pollett; K Monique Hollis-Perry; Santina E Maiolatesi; Luca Illinik; Kathleen F Ramsey; Anatalio E Reyes; Yolanda Alcorta; Mimi A Wong; Julian Davies; Orlando Ortega; Edward Parmelee; Alyssa R Lindrose; Matthew Moser; Elizabeth Graydon; Andrew G Letizia; Christopher A Duplessis; Anuradha Ganesan; Kathleen P Pratt; Allison M Malloy; David W Scott; Stephen K Anderson; Andrew L Snow; Clifton L Dalgard; John H Powers; David Tribble; Timothy H Burgess; Christopher C Broder; Edward Mitre
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

4.  Clinicopathological implications of human papilloma virus (HPV) L1 capsid protein immunoreactivity in HPV16-positive cervical cytology.

Authors:  Sung-Jong Lee; Ah-Won Lee; Chang-Suk Kang; Jong-Sup Park; Dong-Choon Park; Eun-Young Ki; Keun-Ho Lee; Joo-Hee Yoon; Soo-Young Hur; Tae-Jung Kim
Journal:  Int J Med Sci       Date:  2013-12-20       Impact factor: 3.738

5.  E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma.

Authors:  Youn Jin Choi; Ahwon Lee; Tae Jung Kim; Hyun Tak Jin; Yong Bok Seo; Jong Sup Park; Sung Jong Lee
Journal:  J Gynecol Oncol       Date:  2018-02-01       Impact factor: 4.401

Review 6.  Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection.

Authors:  Lungelo Ntuli; Andile Mtshali; Gugulethu Mzobe; Lenine Jp Liebenberg; Sinaye Ngcapu
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

7.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

Authors:  J C Steele; C H Mann; S Rookes; T Rollason; D Murphy; M G Freeth; P H Gallimore; S Roberts
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

8.  New Approaches to Immunotherapy for HPV Associated Cancers.

Authors:  Anne-Sophie Bergot; Andrew Kassianos; Ian H Frazer; Deepak Mittal
Journal:  Cancers (Basel)       Date:  2011-09-02       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.